We’re

/vairˈoo/

Veru Inc. is an oncology and urology biopharmaceutical company developing and commercializing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals.

PHARMACEUTICALS

VERU-111

VERU-111

A novel oral selective antitubulin that targets alpha and beta tubulin for metastatic prostate cancer as well as for other forms of advanced cancers.

Zuclomiphene citrate

Zuclomiphene citrate

Estrogen receptor agonist for the treatment of hot flashes caused by prostate cancer hormonal therapies in men with advanced prostate cancer.

VERU-100

VERU-100

VERU-100 is a novel, proprietary peptide formulation designed with multiple beneficial clinical attributes addressing the shortfalls of the current multi-billion-dollar androgen deprivation therapy market for advanced prostate cancer.

Tadalafil 5mg and Finasteride 5mg combination tablet (TADFIN®)

Tadalafil 5mg and Finasteride 5mg combination tablet (TADFIN®)

TADFIN® combination of a PDE5 inhibitor and 5 alpha reductase inhibitor for the treatment of enlarged prostate (BPH)

LATEST NEWS

2019 Cantor Fitzgerald Global Healthcare Conference

October 2, 2019

Watch the replay of the webcast of our presentation at the 2019 Cantor Fitzgerald Global Healthcare Conference.

Oppenheimer Fall Summit

September 23, 2019